Exelixis' Partner Ipsen Announces EC Approval of CABOMETYX for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma; Triggers $50M Milestone Payment to Exelixis
Benzinga Newdesk